GO analysis of these 770 core target genes revealed enrichment in leukemia stem cell maintenance (e.g., Hoxa9, Meis1, Flt3), hemopoiesis (e.g., Runx1, Runx2, Cd34, Kit), negative regulation of cell differentiation (e.g., Gata2, Ldb1, Ptk2b), and cell proliferation (e.g., Ccnd1, Cdkn2c) (Fig. 6K; Additional file 2: Table S5), which is consistent with oncogenic potential of KAT6A fusions. The gene discussed is KAT6A; the disease is leukemia.